EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and Validation of an Endometrial Cancer Algorithm in US Claims Data

Kimberly Daniels iD, Cachet Wenziger, Sampada Gandhi, Kevin Schott, Li Wang, Bahar Coley, Steven Goldstein, Lauren Parlett iD, Saravanan Shanmugasandaram, Kevin Wolter, Feng Dai, Pejman Azarmina und 1 weitere

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70306 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Kimberly Daniels und 12 weiteren Autor:innen. Beteiligte Einrichtung: Carelon Research, Wilmington, Delaware, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Algorithms, Estrogen Replacement Therapy. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study developed and validated algorithms to identify the incidence of endometrial cancer using ICD‐9‐CM and ICD‐10‐CM coding systems as part of a post‐authorization safety study (EU PAS: EUPAS45602) of vaginal estrogen, estrogen and progestin combination hormone therapy, and non‐users of vaginal estrogen.

Methods

Using national claims data in the HealthCare Integrated Research Database, provisional endometrial cancer cases were identified using a screening algorithm comprising at least one endometrial cancer diagnosis code at any location and position between January 1, 2007 and December 31, 2021. One medical record per case was obtained for 700 provisional cases. Two experts in obstetrics and gynecology adjudicated the medical records classifying each patient as a confirmed case, confirmed non‐case, or unknown. Positive predictive value (PPV), conditional sensitivity assuming all cases were identified by the screening algorithm, and their respective 95% confidence intervals (CI) were calculated. Algorithms were generated by choosing the codes and number of encounters to balance endometrial cancer detection and false positives. Algorithms were trained in a sample of non‐users of vaginal estrogen and tested across treatment groups.

Results

Among the non‐user training set, two visits with ICD‐9‐CM code 182.0 or 182.8 had a PPV of 91.2% (85.4%–95.2%) and sensitivity of 99.3% (95.9%–100.0%). Two visits on separate days with ICD‐10‐CM code C54.1, C54.8, or C54.9 had a PPV of 97.0% (93.6%–98.9%) and sensitivity of 99.5% (97.2%–100.0%). PPVs and sensitivities were over 75% across testing set cohorts for both algorithms.

Conclusion

Two visits with an endometrial cancer diagnosis code accurately identified endometrial cancer cases in both coding systems. There were very few false positive endometrial cancer diagnoses. PPVs and sensitivities were high and similar in all cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsAlgorithmsEstrogen Replacement TherapyHumansFemaleUnited StatesDatabases, FactualMiddle AgedEstrogensInternational Classification of DiseasesAgedPredictive Value of TestsIncidenceProgestinsAdministration, IntravaginalAdultPrediction Algorithms

Stichwörter der Autor:innen

endometrial cancermenopausepositive predictive valuesensitivityvaginal estrogenvalidation

Substanzen

EstrogensProgestins

Autor:innen und Institutionen

  • Carelon Research, Wilmington, Delaware, USA.
  • Pfizer Inc, New York, New York, USA.
  • New York University Grossman School of Medicine, New York, New York, USA.

ORCID-Profile: Kimberly Daniels, Lauren Parlett

Förderung

  • Pfizer

Zitieren

APA

Daniels, K., Wenziger, C., Gandhi, S., Schott, K., Wang, L., Coley, B., Goldstein, S., Parlett, L., Shanmugasandaram, S., Wolter, K., Dai, F., Azarmina, P., & Lanes, S. (2026). Development and Validation of an Endometrial Cancer Algorithm in US Claims Data. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70306

Vancouver

Daniels K, Wenziger C, Gandhi S, Schott K, Wang L, Coley B, et al. Development and Validation of an Endometrial Cancer Algorithm in US Claims Data. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70306

BibTeX
@article{Daniels2026,
  author = {Daniels, Kimberly and Wenziger, Cachet and Gandhi, Sampada and Schott, Kevin and Wang, Li and Coley, Bahar and Goldstein, Steven and Parlett, Lauren and Shanmugasandaram, Saravanan and Wolter, Kevin and Dai, Feng and Azarmina, Pejman and Lanes, Stephan},
  title = {Development and Validation of an Endometrial Cancer Algorithm in US Claims Data},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70306}
}
Kostenlos starten →